Primary Biliary Cholangitis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
(Albany, USA) DelveInsight's, "Primary Biliary Cholangitis Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape. It covers the Primary Biliary Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Biliary Cholangitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Primary Biliary Cholangitis Research. Learn more about our innovative pipeline today! @ Primary Biliary Cholangitis Pipeline Outlook [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Takeaways from the Primary Biliary Cholangitis Pipeline Report

* In June 2025, GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter (IBAT), for the treatment of cholestatic pruritus in patients with PBC, a rare autoimmune liver disease. The Prescription Drug User Fee Act (PDUFA) goal date is 24 March 2026.
* In May 2025, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO Registered (elafibranor) during the European Association for the Study of the Liver congress. Late-breaking exploratory data highlights the impact of IQIRVO Registered (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis.
* In February 2025, Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment option for people living with the rare liver disease in the European Economic Area (EEA).
* GlaxoSmithKline's Linerixibat, an IBAT inhibitor currently in Phase III trials, targets the debilitating pruritus associated with PBC. Additionally, COUR Pharmaceuticals' CNP-104 secured FDA Orphan Drug Designation in January 2025, positioning it as potentially the first disease-modifying treatment for PBC by inducing tolerance to pathogenic activated PDC-E2 T-cells that drive bile duct inflammation.
* In January 2025, COUR Pharmaceuticals, a clinical-stage biotech company focused on developing disease-modifying therapies for immune-mediated diseases, has received Orphan Drug Designation (ODD) from the FDA for CNP-104, a treatment for primary biliary cholangitis (PBC).
* In November 2024:- GlaxoSmithKline- This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants.
* In November 2024:- Mirum Pharmaceuticals Inc.- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
* In November 2024:- Intercept Pharmaceuticals- A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid.
* DelveInsight's Primary Biliary Cholangitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Primary Biliary Cholangitis treatment.
* The leading Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
* Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.

Stay informed about the cutting-edge advancements in Primary Biliary Cholangitis Treatments. Download for updates and be a part of the revolution in cancer care @ Primary Biliary Cholangitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Primary Biliary Cholangitis Emerging Drugs Profile

- Elafibranor: Genfit

Elafibranor is a dual agonist of the PPAR and PPAR. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities. It has shown highly significant results in its Phase 2 Study in patients with primary biliary cholangitis (PBC), while maintaining a favorable tolerability profile and lack of demonstrated safety concerns, paving the way for advancement into phase 3 clinical trial in 2020. It has recently been granted Breakthrough Therapy Designation by the FDA for the treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA), as well as Orphan Drug Designation by the FDA and the EMA (European Medicines Agency).

- ASC42: Gannex Pharma

ASC42 is a novel non-steroidal, selective, potent FXR agonist. It has shown positive results in its Phase I Study in patients with primary biliary cholangitis with no pruritus observed and LDL-C remained within normal range at the human therapeutic dose of 15 mg. The drug is in Phase II stage of its clinical studies for Primary Biliary Cholangitis.

- OP-724: Ohara Pharmaceutical

OP-724 is a synthetic small molecule which is an inhibitor of cyclic AMP response element-binding protein (CREB)-binding protein (CBP)/-catenin. Ohara Pharmaceutical obtained development rights for OP-724 from PRISM BioLab in 2018. The drug is in Phase I stage of its clinical studies for Primary Biliary Cholangitis.

Learn more about Primary Biliary Cholangitis Drugs opportunities in our ground breaking Primary Biliary Cholangitis Research and development projects @ Primary Biliary Cholangitis Unmet Needs [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Primary Biliary Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Primary Biliary Cholangitis Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Primary Biliary Cholangitis Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Primary Biliary Cholangitis Pipeline Report

* Coverage- Global
* Primary Biliary Cholangitis Companies- Gilead Sciences (NASDAQ: GILD), Intercept Pharmaceuticals (NASDAQ: ICPT), CymaBay Therapeutics (NASDAQ: CBAY), COUR Pharmaceuticals, Teva Pharmaceutical (NYSE: TEVA), Mylan, AbbVie (NYSE: ABBV), Glenmark Pharmaceuticals (NSE: GLENMARK), Allergan, Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), Pfizer (NYSE: PFE), Roche (SWX: ROG), Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), AstraZeneca (NASDAQ: AZN), GlaxoSmithKline (NYSE: GSK), Takeda (NYSE: TAK), Amgen (NASDAQ: AMGN), Boehringer Ingelheim, Dr. Reddy's (NYSE: RDY), Amneal (NASDAQ: AMRX), Alnylam (NASDAQ: ALNY), Ionis (NASDAQ: IONS), Arrowhead (NASDAQ: ARWR), CureVac (NASDAQ: CVAC), Sangamo (NASDAQ: SGMO), Calliditas Therapeutics (NASDAQ: CALT), NGM Biopharmaceuticals (NASDAQ: NGM), Bluebird Bio (NASDAQ: BLUE), Intellia (NASDAQ: NTLA), Albireo, TARGET PharmaSolutions, Genfit (NASDAQ: GNFT), and Ascletis Pharma, among others.
* Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.
* Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Primary Biliary Cholangitis Pipeline on our website @ Primary Biliary Cholangitis Drugs and Companies [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

1. Introduction

2. Executive Summary

3. Primary Biliary Cholangitis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Primary Biliary Cholangitis - DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Elafibranor: Genfit

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. ASC42: Gannex Pharma

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. OP-724: Ohara Pharmaceutical

15. Drug profiles in the detailed report.....

16. Inactive Products

17. Primary Biliary Cholangitis Key Companies

18. Primary Biliary Cholangitis Key Products

19. Primary Biliary Cholangitis- Unmet Needs

20. Primary Biliary Cholangitis- Market Drivers and Barriers

21. Primary Biliary Cholangitis- Future Perspectives and Conclusion

22. Primary Biliary Cholangitis Analyst Views

23. Primary Biliary Cholangitis Key Companies

24. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-biliary-cholangitis-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.